Current Report · Items 2.02, 9.01 · 8-K
Lexicon Pharmaceuticals, Inc.
LXRXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operation and Financial Condition On August 6, 2026, we issued a press release to report our financial results for the quarter ended June 30, 2026. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.…
Company context
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.
Current securities
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02
Results of Operation and Financial Condition
On August 6, 2026, we issued a press release to report our financial results for the quarter ended June 30, 2026. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.